How is FOXO4-DRI administered?
This describes how FOXO4-DRI is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a pulsed dosing, not continuous schedule, generally over short pulses (3-5 days). Specific dosing is individual and beyond general information, and human evidence for FOXO4-DRI is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Pulsed dosing, not continuous
- Cycle length: Short pulses (3-5 days)
- Half-life: ~hours
References
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging — Baar MP et al., Cell, 2017
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline — Alameen AAM et al., Naunyn-Schmiedeberg's Arch Pharmacol, 2026
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation — Kong YX et al., Communications Biology, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on FOXO4-DRI
Last updated 2026-06-15.